Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 5/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.42 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.42 |
| ▸ | SCN1A | P35498 | 1/20 | 0.42 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.42 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9700130 | 0.80 | ADRA2A (0.56) | MCHR1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL9700463 | 0.79 | ADRA2A (0.58) | MCHR1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL5582527 | 0.79 | ALDH1A1 (0.48) | MCHR1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL3938782 | 0.79 | HSD17B10 (0.34) | HTR1A | |
| SCHEMBL9701594 | 0.77 | HTR1A (0.53) | ADRA2AADRA2BADRA2CADRA1DADRA1A | |
| SCHEMBL14454772 | 0.75 | MCHR1 (0.42) | MCHR1ADRA2AADRA2CALDH1A1 | |
| SCHEMBL5398026 | 0.75 | ADRA2A (0.65) | MCHR1ADRA2AADRA2BADRA2CADRA1D | |
| SCHEMBL18143470 | 0.74 | KDM4E (0.30) | — | |
| SCHEMBL16851355 | 0.74 | KDM4E (0.30) | — | |
| SCHEMBL18143171 | 0.73 | MAPKAPK2 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-20070173498-A1 | Melanin concentrating hormone antagonist | KATO KANEYOSHI | 2007-07-26 | — | — | US | disclosed |
| US-7115750-B1 | Melanin concentrating hormone antagonist | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173498-A1 | Melanin concentrating hormone antagonist | MC1R, MCHR1, MCHR2 | MCHR1 2/4885ADRA2A 204/4885ADRA2B 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.